Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau reported Q1 2026 results with a net loss of $22.9 million, widening from $8.7 million in the prior year, driven largely by a $9.6 million charge from warrant liability remeasurement. The company highlighted strong clinical progress, including 100% local disease control in early glioblastoma and pancreatic cancer trials, and the completion of enrollment in its pivotal ReSTART trial for cutaneous squamous cell carcinoma.
Key figures
- Revenue
- 0
- Net loss
- 22939000
- Rd expense
- 10975000
- Restart enrollment
- 88
- Cash and equivalents
- 80200000
- Gaming response rate gb M
- 67%
- Local disease control gb M
- 100%
- Local disease control pancreatic
- 100%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.